Lonza successfully starts up Nansha API facility

Published: 23-Jan-2009
Media Ingredients

Lonza, a Swiss supplier of APIs, has successfully concluded the first phase of the expansion of its Nansha plant in Guangzhou, China.


Lonza, a Swiss supplier of APIs, has successfully concluded the first phase of the expansion of its Nansha plant in Guangzhou, China.

The new US$200m (Euro 155m) six-train API facility combines state-of-the art facilities, industry-leading development services and advanced cGMP chemical manufacturing plants.

Production in the first train was successfully started in December 2008 with the first customer product.

The fully integrated site supports modern utilities, administration, r&d, kilo-lab and both small- and large-scale production. 70 scientists are supporting r&d, in a 1,000m2 lab area.

"This investment enables us to continue addressing the needs of our expanding worldwide customer base by adding manufacturing capacity, expanding our r&d services and increasing flexibility," said Lonza ceo Stefan Borgas.

The first phase of the small-scale plant in Nansha started operations in September 2007 with the aim of building a bridge between the kilo-lab and commercial-scale production.

Further expansion has been initiated with the construction of the next phase extensions (small- and large-scale plants).

  • Companies:
  • Lonza
See more

You may also like

Ingredients

Staying ahead of the ADC curve

Read more
Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules

Trending Articles

  1. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  2. Can Aztekin receives Rising Star Award 2025 from the International Society of Regenerative Biology
  3. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  4. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  5. Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Lonza to supply prequalified cells for CN Bio OOC technology

Organ-on-a-chip technology has the potential to solve the issues presented by 2D cell cultures and animal models, the companies say
Ingredients

Lonza announces cryopreserved Leukopak offering

Fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation, limiting transportation options
Ingredients

Lonza introduces hi-res HLA-typed primary cell lots

This offering builds on the company’s human primary cell capabilities
Ingredients

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to quickly assess new drug candidates while minimising API consumption
Subscribe now